COMMUNIQUÉS West-GlobeNewswire

Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering
18/03/2026
CUPERTINO, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet [...]
SeaStar Medical to Report Fourth Quarter and Year-End 2025 Financial Results on March 25, 2026
18/03/2026
DENVER, March 18, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and [...]
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
18/03/2026
FOSTER CITY, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that, effective March 17, 2026, it granted stock options to purchase [...]
Serina Therapeutics Secures up to $30 Million in Private Placement to Advance Registrational Trial of SER-252 for Advanced Parkinson’s Disease
18/03/2026
- First tranche of $15 million expected to close on March 20, 2026; second tranche of up to $15 million available, for up to $30 million in total proceeds from the sale of common stock and pre-funded warrants priced at [...]
Positive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate
19/03/2026
Based on the Strength of Unprecedented Results from the Positive Phase 1/2 Study in Adults Aged 50 and Older, Vaxcyte Advanced VAX-31 High Dose into Comprehensive Phase 3 Adult Program; Topline Data from the OPUS-1 [...]
Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results
18/03/2026
Phase 1 APOLLO data update demonstrated encouraging clinical activity with a 66% objective response rate in relapsed non-Hodgkin lymphoma, including 50% complete responses Research published in Nature Medicine [...]
SnoreStop Throat Spray Claims Evaluated: Effective Anti-Snoring Oral Solution with Clinically Proven Ingredients
18/03/2026
A 2026 source-based informational overview of SnoreStop's doctor-developed oral spray formula as described in company materials, cited clinical study references, homeopathic ingredient research context, pricing [...]
Ever Joint Claims Evaluated: What the Science Says About EverJoint Joint Support Ingredients
18/03/2026
A 2026 company-issued informational report outlining how Ever Joint positions its joint support formula, ingredient-level research context, oxidative stress claims, pricing structure, and what consumers should verify [...]
BBOT Announces Multiple Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026
18/03/2026
SOUTH SAN FRANCISCO, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today [...]
Extendicare Announces Proposed Changes to Board of Directors
18/03/2026
MARKHAM, Ontario, March 18, 2026 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) today announced that its board of directors (“Board of Directors” or “Board”) has nominated Josh Blair [...]
Tonix Pharmaceuticals to Present at BIO-Europe Spring 2026
18/03/2026
BERKELEY HEIGHTS, N.J., March 18, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated, commercial biotechnology company, announced today that Seth [...]
Big Ed's Meds Under Investigation: Safe FDA-Approved ED Medications for Men
18/03/2026
A company-informational report from Big Eds Meds LLC addressing common consumer search questions about the Big Ed's Meds telehealth platform, FDA-approved generic ED medication access, pricing, provider standards, and [...]
ImmuCell Appoints Former Elanco Animal Health Board Member Kathy Turner to Board
18/03/2026
PORTLAND, Maine, March 18, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops, manufactures and markets products to improve calf [...]
Alvotech Q4 2025 and Full Year 2025 Financial Results
18/03/2026
A supplemental long ‑ form earnings release providing additional operational details and business update for Q4 2025 and the full year is available at: https://investors.alvotech.com/earnings-calendar The supplemental [...]
ADR Ratio Change
18/03/2026
March 18, 2026 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) ADR Ratio Change Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative [...]
ProKidney Reports Full Year 2025 Financial Results and Business Highlights
18/03/2026
On track to complete enrollment for the Phase 3 PROACT 1 accelerated approval analysis of rilparencel in mid-2026; anticipate pivotal topline results in Q2 2027 In a July 2025 Type B meeting, aligned with FDA on the [...]
Red Boost Claims Evaluated: The Male Performance Powder Under Investigation
18/03/2026
A 2026 informational report covering how Red Boost describes its smooth muscle marketing claims, male sexual performance ingredient research context, pricing structure, and what consumers should know before purchasing [...]
Dr. Austin Harris Revolutionizes Mental Health and Pain Management with Personalized, Integrative Ketamine Therapy
18/03/2026
SHERMAN OAKS, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Dr. Austin Harris , a board-certified cardiothoracic anesthesiologist and the founder of NeuroRelief Ketamine & Infusion Therapy, is redefining the treatment [...]
BioPorto Successfully Completes Preliminary Analysis of U.S. Adult NGAL Cutoff Study; Pre-Submission expected by End of Q1 2026
18/03/2026
March 18, 2026 Announcement no. 03 BioPorto Successfully Completes Preliminary Analysis of U.S. Adult NGAL Cutoff Study; Pre-Submission expected by End of Q1 2026 COPENHAGEN, DENMARK, March 18, 2026 – BioPorto A/S (“ [...]

Pages